Bone ameloblastoma

Summary

Bone ameloblastoma (MONDO:0000513) is a disease. A subtype of bone benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bone ameloblastoma
Mondo ID	MONDO:0000513
DOID	DOID:0050895
GARD	0022782
Anatomy (UBERON)	UBERON:0002481
Is cancer (heuristic)	no

Also known as: ameloblastoma of bone tissue · bone tissue ameloblastoma

Disease family

This is a subtype of bone benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system benign neoplasm › benign connective and soft tissue neoplasm › bone benign neoplasm › bone ameloblastoma

Related subtypes (18): phalanx chondroma, ossifying fibroma, periosteal chondroma, chondroblastoma, osteoma, paranasal sinus Schneiderian papilloma, osteoid osteoma, CHILD syndrome, chondromyxoid fibroma, craniopharyngioma, osteoblastoma, benign neoplasm of pituitary gland, benign neoplasm of sphenoidal sinus, benign neoplasm of frontal sinus, benign neoplasm of maxillary sinus, benign neoplasm of ethmoidal sinus, benign neoplasm of lower jaw bone, desmoplastic fibroma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.